# A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

> **NCT06835972** · PHASE1,PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 43 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Translocation Renal Cell Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT06835972
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06835972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06835972, "A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06835972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*